Pharma Industrial India - Professional magazine for pharma industry suppliers and lab technology

NEWS ABOUT >

Biotechnology

Clean Rooms

Clinical Trials

Consultants

Digitalization

Drug Discovery & Development

Engineering

Global Pharma

Industrial talks

Ingredients

Lab Equipment

Logistics & Distribution

Manufacturing

Market

Outsourcing

Packaging

Quality / GMP

Regulation

Safety

Last edition

All magazines
Subscribe to our magazine

News about "Racura Oncology"

Racura Oncology Doses First Patient in Phase 1 Trial of RC220 Combination Therapy for EGFR-Mutant Lung Cancer

HARNESS-1 study evaluates RC220 with osimertinib to address treatment resistance in EGFR-mutant non-small cell lung cancer, with the first patient showing no adverse events after initial dosing.

Racura Oncology | 26/06/2026 | By News Bureau

Racura Oncology Advances RC220 to Higher Dose Level in Phase 1 CPACS Cancer Trial

Racura Oncology has received approval from the Safety Review Committee to escalate the dose of investigational cancer therapy RC220 in its phase 1 CPACS clinical trial following positive safety findings in advanced metastatic cancer patients.

Racura Oncology | 19/05/2026 | By News Bureau | 105

We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.

More information: Privacy Policy

pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members